6 questions answered from cited research · Plain language
Yes, new immunomodulation strategies for liver fibrosis focus on reprogramming macrophages, targeting specific immune subsets, and using metabolic therapies like GLP-1 analogues and THRβ activators.
Read the full answer →Nanotechnology shows promise for treating liver fibrosis by delivering drugs directly to liver cells, improving how treatments work, and reducing side effects compared to traditional methods.
Read the full answer →New antifibrotic therapies focus on reprogramming immune cells like macrophages and using metabolic drugs that reduce liver fat, rather than just targeting scar tissue directly.
Read the full answer →Specific genetic variants in the PON1 gene can change how well the enzyme works, which directly influences a person's risk for developing liver fibrosis and related metabolic issues.
Read the full answer →Machine learning models analyze patient data to predict liver fibrosis with moderate accuracy, often outperforming traditional tests like FIB-4, but they are not yet standard in clinical practice.
Read the full answer →Yes, gene modulation is a promising experimental approach for liver fibrosis and MASH, with several strategies showing preclinical success, though human treatments are not yet available.
Read the full answer →